{
    "clinical_study": {
        "@rank": "158056", 
        "arm_group": [
            {
                "arm_group_label": "Liraglutide"
            }, 
            {
                "arm_group_label": "DPP-4"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is conducted in Europe. The aim of this study is to demonstrate the clinical\n      effectiveness and safety of liraglutide and dipeptidyl peptidase-4 (DPP-4) inhibitor therapy\n      in routine primary care in Europe."
        }, 
        "brief_title": "Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients treated with liraglutide or DPP-4 inhibitors, according to license in\n             respective participating country with data available for 12 (+/- 2) months\n\n        Exclusion Criteria:\n\n          -  Patients treated with liraglutide or DPP-4 inhibitors, outside of license in\n             respective participating country"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Consecutive patients with type 2 diabetes initiated on liraglutide or a DPP-4 inhibitor\n        and primarily managed in primary care with 12 (+/-2) months of available data will be\n        included in this study. Only data derived from patients receiving either therapy in\n        accordance with license indications will be included and analyzed."
            }
        }, 
        "enrollment": {
            "#text": "1392", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01890993", 
            "org_study_id": "NN2211-4077", 
            "secondary_id": "U1111-1142-2764"
        }, 
        "intervention": {
            "arm_group_label": [
                "Liraglutide", 
                "DPP-4"
            ], 
            "description": "Anonymised patient level data will be collected by the patients' own general practitioner and electronic case report form (eCRF) will be used to capture the data.", 
            "intervention_name": "No treatment given", 
            "intervention_type": "Other"
        }, 
        "intervention_browse": {
            "mesh_term": "Dipeptidyl-Peptidase IV Inhibitors"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 17, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Paris La d\u00e9fense cedex", 
                        "country": "France", 
                        "zip": "92932"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mainz", 
                        "country": "Germany", 
                        "zip": "55127"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28033"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Crawley", 
                        "country": "United Kingdom", 
                        "zip": "RH11 9RT"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "Germany", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_groups": "2", 
        "official_title": "Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": [
                "France: Ministry of Health", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Spain: Ministry of Health", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in HbA1c (glycosylated haemoglobin)", 
            "safety_issue": "No", 
            "time_frame": "Baseline (anytime within 3 months before therapy initiation), month 12 (+/-2)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01890993"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in body weight", 
                "safety_issue": "No", 
                "time_frame": "Baseline (anytime within 3 months before therapy initiation), month 12 (+/-2)"
            }, 
            {
                "measure": "Change in systolic blood pressure", 
                "safety_issue": "No", 
                "time_frame": "Baseline (anytime within 3 months before therapy initiation), month 12 (+/-2)"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}